About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study In Patients With Dyslipidaemia | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00264667

Study In Patients With Dyslipidaemia

Study in patients with dyslipidaemia.

Lead sponsor: GlaxoSmithKline•50 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

GlaxoSmithKline

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Waist circumference =102cm (men) or =88cm (women) at visit 1.
•Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1.
•Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1.
•Subjects whose plasma LDL C concentration does not require treatment according to the NCEP ATP III guidelines at Screening Visit 1.

Exclusion Criteria

•History of diabetes
•History of cardiovascular disease
•Diagnosis of genetic lipid disorders
•History of muscle pain
•History of cancer

Related studies

Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells.

NCT06801769 · Pancreatic Steatosis, Metabolic Syndrome X, and more

Identification of a Score for the Assessment of Intrapancreatic Fat

NCT07155473 · Pancreatic Steatosis, Metabolic Syndrome X, and more

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

NCT06661655 · Metabolic Syndrome X, Fatty Liver, and more

Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)

NCT06650943 · First Episode Psychosis (FEP), Metabolic Syndrome X

The Early Warning System for the Diabetic Encephalopathy

NCT02420470 · Diabetes Mellitus Type 2, Mild Cognitive Impairment, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 28, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment290

Start dateDec 2005

Last updatedOct 28, 2016

Condition

Metabolic Syndrome X

Locations shown

GSK Investigational Site

Buenos Aires, Buenos Aires

GSK Investigational Site

Córdoba, Córdoba Province

GSK Investigational Site

Buenos Aires

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions